Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Restricted access

According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations.

Correspondence: Anthony J. Olszanski, MD, RPh, Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Email: anthony.olszanski@fccc.edu
  • 1.

    Gershenwald JE, Scolyer RA, Hess KR, Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–492.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199–6206.

  • 3.

    Morton DL, Thompson JF, Cochran AJ, Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370:599–609.

  • 4.

    Faries MB, Thompson JF, Cochran AJ, Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376:2211–2222.

  • 5.

    Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681–1696.

  • 6.

    Omholt K, Platz A, Kanter L, NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9:6483–6488.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Hauschild A, Dummer R, Schadendorf D, Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma [published online October 22, 2018]. J Clin Oncol, doi: 10.1200/JCO.18.01219

    • Search Google Scholar
    • Export Citation
  • 8.

    Eggermont AM, Chiarion-Sileni V, Grob JJ, Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522–530.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Weber J, Mandala M, Del Vecchio M, Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824–1835.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 337 337 9
PDF Downloads 151 151 6
EPUB Downloads 0 0 0